Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. was founded to develop targeted small-molecule drugs to treat life-threatening cancers. The company’s lead drug was CX-3543, which was developed through Phase II clinical trials.

Investors

• Research Corporation Technologies
• Sanderling Ventures
• Novartis BioVentures
• IngleWood Ventures
• Coastview Capital
• BioVentures Investors
• Mitsui & Co. Venture Partners
• Morningside Venture Investments
• TDL Investors
• William Harris Investors
• Lakeview Capital
• The Viterbi Group
• HBM BioVentures
• Lilly Ventures.

Inventors/Founders

• Laurence Hurley, Ph.D., D.Sc.
  University of Arizona
  (Hurley discovered and initially developed the Cylene technologies while at the University of Texas at Austin)
• Daniel D. Von Hoff, M.D.
  Unversity of Arizona